Why Is GSK Up Today?

GSK plc (LSE:GSK) shares rose 1.22% to 1,910.0p today, a gain of 23.0p on the session. The global biopharma group remains in focus following a third-quarter update that showed growth in specialty medicines and a steady run of pipeline milestones.

In the quarter, group sales reached £8.9 billion, up 5% at constant exchange rates, while core operating profit rose 5%. Management reaffirmed its full-year outlook for 2026.

About GSK plc

GSK plc is a global biopharmaceutical company that discovers, develops and supplies vaccines, specialty medicines and general medicines. Its portfolio spans respiratory conditions, HIV, oncology, immunology and infectious disease, and its products reach patients in more than 100 countries.

LSE:GSK has a 2.93% weighting in the FTSE 100 and a Market Capitalisation of about £76.3 billion, making it one of the larger healthcare names in the index.

Third-Quarter Sales Performance

Total sales of £8.9 billion were 4% higher at actual exchange rates and 5% higher at constant exchange rates. The mix of the Business continues to evolve, with specialty medicines now the largest contributor.

Specialty Medicines delivered sales of £3.9 billion, an increase of 15%, supported by HIV, oncology and respiratory and immunology products. Vaccines contributed £2.6 billion, while General Medicines was stable at £2.4 billion, providing a dependable base of established brands.

Profit and Earnings

Core operating profit grew 5% in the quarter and core Earnings per share rose 1%. Total operating profit includes a £328 million charge linked to the Accelerate Growth restructuring programme, which is designed to simplify the organisation and direct Investment to priority areas.

Management said it expects 2026 turnover growth of 3% to 5%, core operating profit growth of 7% to 9% and core Earnings Per Share growth of 7% to 9%. Keeping this range unchanged gives investors a clear framework for the final months of the year.

Pipeline Milestones

The quarter included several regulatory and clinical steps. Hibsago received approval in the United States and Japan, and Jemperli received a further approval in the United States. Jideytro was approved in the United States for second-line use following positive registrational data.

In vaccines, a pre-filled syringe presentation of Shingrix was approved in Japan, and a phase III trial of a seasonal mRNA influenza Vaccine has started. GSK also reported that 18 of the 22 phase III trials planned for 2026 have now begun, which reflects the scale of its late-stage programme.

Dividend

A third-quarter Dividend of 17p per share was declared, and the company expects a total of 70p per share for the full year. A regular quarterly dividend is an important part of how GSK returns cash to shareholders while continuing to invest in its pipeline.

Why Pipeline Depth Matters

Medicines development is a long process, and a broad set of programmes across different therapy areas can help a company manage the natural life cycle of its products. GSK's strategy focuses on infectious disease, HIV, oncology and immune-related conditions, areas where scientific advances and unmet patient needs remain significant.

Specialty medicines tend to be differentiated products used by specialist physicians, and growth in this category can influence the group's overall Margin profile over time. Regulatory approvals in several major markets also widen the number of patients who can access new treatments.

Operational Priorities

The Accelerate Growth programme is intended to free up funds for reinvestment in discovery and commercial launches. Alongside this, the company continues to invest in manufacturing, Supply chain reliability and digital tools that support clinical development.

Sustainability also forms part of the agenda, including efforts to reduce emissions across operations and to improve access to medicines and vaccines in lower-income countries. These commitments help support long-term relationships with healthcare systems.

Factors to Monitor

Investors following LSE:GSK may watch further regulatory decisions, progress in phase III trials, vaccine Demand through the winter season, the pace of restructuring and delivery against the reaffirmed 2026 guidance.

Conclusion

GSK plc rose 1.22% to 1,910.0p today following a third-quarter update that showed 5% sales growth at constant exchange rates, specialty medicines growth of 15% and a series of pipeline approvals. The reaffirmed outlook and 70p expected dividend provide additional context. Future company announcements should provide further detail on operating progress, capital allocation and management priorities.